54
Pharma & HealthcareHold
DSP Healthcare
DSP · Direct–Growth · rank #7 of 18 by Smart Score
Data updated
Trailing returns
1 Year
19.4%
+16.4% vs index
3 Years
22.9%
+11.3% vs index
5 Years
15.6%
+5.2% vs index
Since launch
23.5%
Year-by-year performance
2021
+25.1%-5.5% vs index
2022
-6.5%-10.3% vs index
2023
+36.8%+10.3% vs index
2024
+42.6%+27.0% vs index
2025
-4.5%-12.2% vs index
2026
+18.3%+20.3% vs index
Why this score
DSP Healthcare scores 54/100 — #7 of 18 Pharma & Healthcare fund (Hold). It stands out for expense ratio and fund size — beating 92% of peers on expense ratio. The main drag is its alpha (better than only 28% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
Expense ratio0.71% · 92nd percentile in category
Fund size3628.03 Cr · 81st percentile in category
3Y return22.90% · 41st percentile in category
Alpha3.67 · 28th percentile in category
Sortino ratio1.81 · 70th percentile in category
1Y return19.39% · 38th percentile in category
Top holdings
1.Sun Pharmaceutical Industries Ltd8.42%
2.Ipca Laboratories Ltd8.17%
3.Cipla Ltd8.13%
4.Sai Life Sciences Ltd.7.1%
5.Gland Pharma Ltd6.35%
29 disclosed equity positions · portfolio as of Jul 2026 · weights are % of total corpus.